Soligenix Yönetim

Yönetim kriter kontrolleri 4/4

Soligenix's CEO is Christopher Schaber, appointed in Aug 2006, has a tenure of 18.25 years. total yearly compensation is $700.49K, comprised of 74.2% salary and 25.8% bonuses, including company stock and options. directly owns 0.017% of the company’s shares, worth $1.46K. The average tenure of the management team and the board of directors is 10.4 years and 15.4 years respectively.

Anahtar bilgiler

Christopher Schaber

İcra Kurulu Başkanı

US$700.5k

Toplam tazminat

CEO maaş yüzdesi74.2%
CEO görev süresi18.3yrs
CEO sahipliği0.02%
Yönetim ortalama görev süresi10.4yrs
Yönetim Kurulu ortalama görev süresi15.4yrs

Son yönetim güncellemeleri

Recent updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Soligenix announces $2.6M FDA grant to further study blood cancer candidate

Sep 06

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M

Aug 12

Soligenix, SERB Pharma team up to develop therapy for ricin poisoning

Jul 25

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Soligenix inks supply and distribution deal for SGX301 companion light device in cancer

Jan 07

Soligenix receives $1.5M grant advancing COVID-19 vaccine development

Dec 28

CEO Tazminat Analizi

Christopher Schaber'un ücretlendirmesi Soligenix'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$7m

Dec 31 2023US$700kUS$519k

-US$6m

Sep 30 2023n/an/a

-US$8m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$711kUS$499k

-US$14m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$687kUS$485k

-US$13m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$12m

Dec 31 2020US$944kUS$475k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$15m

Dec 31 2019US$688kUS$466k

-US$9m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$9m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$619kUS$453k

-US$9m

Sep 30 2018n/an/a

-US$8m

Jun 30 2018n/an/a

-US$7m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$674kUS$444k

-US$7m

Tazminat ve Piyasa: Christopher's total compensation ($USD700.49K) is about average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Christopher's compensation has been consistent with company performance over the past year.


CEO

Christopher Schaber (58 yo)

18.3yrs

Görev süresi

US$700,485

Tazminat

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Schaber
Chairman of the Board of Directors18.3yrsUS$700.49k0.017%
$ 1.5k
Jonathan Guarino
Senior VP5.2yrsUS$354.69k0.0020%
$ 177.8
Oreola Donini
Senior VP & Chief Scientific Officer9.9yrsUS$387.59k0%
$ 0
Richard Straube
Senior VP & Chief Medical Officer10.8yrsUS$249.94k0.0015%
$ 131.2

10.4yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: SNGX's management team is seasoned and experienced (10.4 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Schaber
Chairman of the Board of Directors18.3yrsUS$700.49k0.017%
$ 1.5k
Jerome Zeldis
Independent Director13.4yrsUS$72.50k0.0042%
$ 370.6
Gregory Lapointe
Independent Director15.7yrsUS$77.50k0.0014%
$ 119.7
Robert Rubin
Independent Director15.1yrsUS$80.00k0.00083%
$ 73.1
Dorothy Mary Keefe
Member of Oral Mucositis Medical Advisory Boardno dataVeri yokVeri yok
Jeffrey Hyams
Member of Pediatric Crohn's Disease Medical Advisory Boardno dataVeri yokVeri yok
James Markowitz
Member of Pediatric Crohn's Disease Medical Advisory Boardno dataVeri yokVeri yok
Joel Rosh
Member of Pediatric Crohn's Disease Medical Advisory Boardno dataVeri yokVeri yok
Alain Rook
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno dataVeri yokVeri yok
Mark Schubert
Member of Oral Mucositis Medical Advisory Boardno dataVeri yokVeri yok
Youn Kim
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno dataVeri yokVeri yok
Gary Wood
Member of Cutaneous T-Cell Lymphoma Medical Advisory Boardno dataVeri yokVeri yok

15.4yrs

Ortalama Görev Süresi

69.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SNGX's board of directors are seasoned and experienced ( 15.4 years average tenure).